Factores asociados a respuesta de abatacept subcutaneo en artritis reumatoide

dc.contributorSarmiento Monroy, Juan Camilo
dc.contributorMantilla Hernández, Rubén Darío
dc.creatorRodríguez López, Julieth Milena
dc.date.accessioned2016-07-05T19:39:52Z
dc.date.available2016-07-05T19:39:52Z
dc.date.created2016-07-05T19:39:52Z
dc.date.issued2016
dc.identifierhttp://repository.urosario.edu.co/handle/10336/12183
dc.identifierhttps://doi.org/10.48713/10336_12183
dc.description.abstractBACKGROUND Since rheumatoid arthritis is the most common in the world inflammatory arthropathy, being highly disabling and causing great impact of high cost, we seek to offer the patient treatment options and quality of life through the establishment of a timely and effective treatment, recognizing those prior to establish predictors of response given therapy. There are few studies to establish those factors appropriate response to the start of biological therapy with abatacept, so this study is to determine what those factors are possible. METHODS This was a cross-sectional analytical study of 94 patients diagnosed with RA, assessed to determine possible variables that influence the biological response to abatacept therapy type. 67 were included in the regression model, which are those patients in whom it was possible to measure the response to treatment (EULAR response) through the determination of the DAS 28 and thus discriminate two comparison groups (response and nonresponse ). DISCUSSION OF RESULTS The presence of high activity of the disease at the start of biological therapy increases the likelihood of response to treatment compared to the group with low /moderate disease activity; OR 4.19 - 95% CI (1.18 - 14.9), (p 0.027). The absence of bone erosions increases the probability of adequate response to biological therapy compared with those erosions, with an OR 3.1 (1.01 to 9.55), (p 0.048). ESR and the presence of extra-articular manifestations: other data of interest in the bivariate analysis found. Regarding the variables or characteristics as predictors of response to treatment with abatacept, they are studies that corroborate the findings of this study, regarding the high DAS 28 score at the start of therapy (9, 12). CONCLUSIONS There are several variables that determine the biological response to different handling of AR. It is essential to assess these factors individually in order to achieve effectively control the disease and improve the quality of life of the individual (personalized medicine). There are variables such as high disease activity and the absence of erosions as predictors of response in abatacept therapy.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherFacultad de medicina
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto completo)
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.sourceDelgado-vega AM, Martín J, Granados J, Anaya JM. Epidemiología genética de la artritis reumatoide : ¿ qué esperar de América Latina ? Biomédica. 2006;26:562–84.
dc.sourceBenito Ruiz P, Pros Simón a. ¿Por qué un tratamiento precoz en la artritis reumatoide? Medifam. 2001;11(6):335–41.
dc.sourceGómez Rodríguez N. Repercusión socioeconómica de la artritis reumatoide. An Med Interna. 2003;20(3):111–3.
dc.sourceChaves Chaparro LM, Salvatierra Ossorio J, Raya Álvarez E. Factores predictores de respuesta a terapias biológicas en la artritis reumatoide. Reumatol Clin. 2011;7(2):141–4.
dc.sourceSmolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75
dc.sourceK, Kavanaugh AF, Rubbert-roth A, Ferraccioli G. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. Rheumatol (United Kingdom). 2012;51(SUPPL.5):12–21
dc.sourceBurgos-Vargas R, Catoggio LJ, Galarza-Maldonado C, Ostojich K, Cardiel MH. Current therapies in rheumatoid arthritis: A Latin American perspective. Reumatol Clin. 2013;9(2):106–12.
dc.sourceDisease Activity Score in 28 Joints ( DAS28 ). Available at http://www.das-score.nl/www.das-score.nl/index.html. Accessed April 15, 2010
dc.sourceDaïen CI, Morel J. Predictive factors of response to biological disease modifying antirheumatic drugs: Towards personalized medicine. Mediators Inflamm. 2014;2014
dc.sourceH. Yamanaka, Y. Tanaka, E. Inoue et al., “Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study),”Modern Rheumatology, vol. 21, no. 2, pp. 122–133, 2011
dc.sourceR. J. Maneiro, E. Salgado, L. Carmona, and J. J. Gomez-Reino, “Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis,” Seminars in Arthritis and Rheumatism, vol. 43, no. 1, pp. 9–17, 2013.
dc.sourceJ. E. Gottenberg, P. Ravaud, A. Cantagrel et al., “Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the “Orencia and Rheumatoid Arthritis“ registry,” Annals of the Rheumatic Diseases, vol. 71, no. 11, pp. 1815–1819, 2012.
dc.sourceLima VT, Lima a. MT, Cuéllar MVH, Relova RA. Inmunopatogenia de la artritis reumatoidea. Conceptos actuales. Rev Cuba Med Gen Integr. 1998;14(5):429–33.
dc.sourceMohammed RH a, Farahat F, Kewan HH, Bukhari M a. Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease. Springerplus [Internet]; 2015;4(1). Available from: http://www.springerplus.com/content/4/1/207
dc.sourceSimsek I. Predictors of Response to TNF Inhibitors in Rheumatoid Arthritis. Bull NYU Hosp Jt Dis. 2012;70(3):187–90.
dc.sourceMikuls TR, Saag KG, Criswell LA, Merlino LA, Kaslow RA, Shelton BJ, et al. prospective cohort of older women : results from the Iowa. 2002
dc.sourceKvien TK, Uhlig T, Ødegård S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Annals of the New York Academy of Sciences. 2006 Jun [cited 2015 Mar 4]; 1069:212–22
dc.sourceKoch AE. The pathogenesis of rheumatoid arthritis. Am J Orthop (Belle Mead NJ). 2007;36(7 Suppl):5–8.
dc.sourceAlamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmunity Reviews. 2005;4(3):130–6
dc.sourceJansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs - a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014;12(1):102.
dc.sourceSzkudlarek M, Narvestad E, Klarlund M, Court-Payen M, Thomsen HS, Østergaard M. Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination. Arthritis Rheum. 2004 ;50(7):2103–12.
dc.sourceGómez A. Nuevos criterios de clasificación de artritis reumatoide. Reumatol Clin. 2010;6(SUPPL. 3):33–7.
dc.sourceKhraishi MM. Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians. Ther Adv Musculoskelet Dis [Internet]. 2014;6(5):159–68.Khraishi MM. Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians. Ther Adv Musculoskelet Dis [Internet]. 2014;6(5):159–68.
dc.sourceAmaya-Amaya J, Torralvo-Morato G, Calixto O-J, Calderón-Rojas R, Caro-Moreno J, Domínguez A-M, et al. Correlación y concordancia de la autoclinimetría en artritis reumatoide: revisión sistemática de la literatura y metanálisis. Rev Colomb Reumatol [Internet]. 2013;20(1):30–57.
dc.sourceRuiz-esquide V, Sanmartí R. Tabaco y otros factores ambientales en la artritis reumatoide. 2015;8(6):342–50.
dc.sourceMartín Mola E, Balsa A, Martínez Taboada V, Sanmartí R, Marenco JL, Navarro Sarabia F, et al. El uso de abatacept en artritis reumatoide: Revisión de la evidencia y recomendaciones.
dc.sourceWells AF, Jodat N, Schiff M. A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations. Biologics [Internet]. 2014;8:41–55. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3933241&tool=pmcentrez&rendertype=abstract
dc.sourceHaye Salinas María Jezabel, Retamozo Soledad, Vetorazzi Lorena, Peano Natalia, Díaz Cuiza Patricia Ericka, Castaños Menescardi María Sol et al . Anticuerpo anticitrulina y manifestaciones extra articulares en artritis reumatoidea. Medicina (B. Aires) 2013; 73( 1 ): 21-25.
dc.sourceJouanen Efrain, Abud-mendoza Carlos, Garza Mario, et. Al. Recommendations for the medical treatment of rheumatoid artritis. Rev. invest. Clín 2005 ; 57.
dc.sourceKokuina Elena, Chico Araceli, Carballar Luiber, et. al. Rheumatoid factor: association with the radiological erosion and with the rheumatoid arthritis activity. La Habana Cuba. Articulo original.
dc.sourceSanmarti Raimon, Gómez-Puerta Jose. Biomarkers in rheumatoid arthritis. Reumatol Clin.2011;6 Supl 3:25-8
dc.sourceSchett, Georg, and Ellen Gravallese. “Bone Erosion in Rheumatoid Arthritis: Mechanisms, Diagnosis and Treatment.” Nature reviews. Rheumatology 8.11 (2012): 656–664.
dc.sourceFrransen Jaap, van Riel Piet. The Disease Activity Score and the EULAR Response Criteria. Elsevier. 2009;35(4): 745- 757.
dc.sourceMoots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford). 2012;51(12):2252–61.
dc.sourcePress D. Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis. 2014;313–20.
dc.sourceRomão VC, Canhão H, Fonseca JE. Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Med [Internet]. BioMed Central Ltd; 2013;11(1):17. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3606422&tool=pmcentrez&rendertype=abstract
dc.sourceRosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med [Internet]. BMC Medicine; 2013;11(1):88. Available from: http://www.biomedcentral.com/1741-7015/11/88
dc.sourceRubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) [Internet]. 2012;51 Suppl 5(March):v38–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22718926
dc.sourceSchiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatol (United Kingdom). 2013;52(6):986–97.
dc.sourceAlamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmunity Reviews. 2005;4(3):130–6
dc.sourceScarsi M, Paolini L, Ricotta D, Pedrini A, Piantoni S, Caimi L, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014;41(4):666–72.
dc.sourceSakkas LI, Bogdanos DP, Katsiari C, Platsoucas CD. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis—relevance to treatment. Autoimmun Rev [Internet]. Elsevier B.V.; 2014;13(11):1114–20. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1568997214001566
dc.sourceSato E, Tanaka E, Ochiai M, Shimizu Y, Kobayashi A, Shidara K, et al. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012. Mod Rheumatol [Internet]. 2015;25(3):350–7. Available from: http://informahealthcare.com/doi/abs/10.3109/14397595.2014.958274
dc.sourcePicchianti Diamanti A, Rosado MM, Scarsella M, Germano V, Giorda E, Cascioli S, et al. Abatacept (CTLA4-Ig) improves B cell function and Treg inhibitory capacity in rheumatoid arthritis patients non responding to anti-TNF-alpha agents. Clin Exp Immunol [Internet]. 2014;4:1–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24773026
dc.sourceTanaka Y, Kubo S, Yamanaka H, Amano K, Hirata S, Tanaka E, et al. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(®) as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheumatol [Internet]. 2014;24(5):754–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25036232
dc.sourceIwahashi M, Inoue H, Matsubara T, Tanaka T, Amano K, Kanamono T, et al. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. Mod Rheumatol [Internet]. 2014;7595(6):1–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24708204
dc.sourceKrüger K, Gaubitz M. Empfehlungen zum einsatz von abatacept bei patienten mit rheumatoider arthritis. Z Rheumatol. 2008;67(7):614–6.
dc.sourceAmano K, Matsubara T, Tanaka T, Inoue H, Iwahashi M, Kanamono T, et al. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders. Mod Rheumatol [Internet]. 2015;7595:1–7. Available from: http://informahealthcare.com/doi/abs/10.3109/14397595.2015.1012786
dc.sourceBaji P, Péntek M, Czirják L, Szekanecz Z, Nagy G, Gulácsi L, et al. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: A mixed treatment comparison. Eur J Heal Econ. 2014;15(SUPPL. 1).
dc.sourceConti F, Ceccarelli F, Massaro L, Cipriano E, Di Franco M, Alessandri C, et al. Biological therapies in rheumatic diseases. Clin Ter. 2013;164(SUPPL.5).
dc.sourceDavis JM, Matteson EL. My treatment approach to rheumatoid arthritis. Mayo Clin Proc [Internet]. Elsevier Inc.; 2012;87(7):659–73. Available from: http://dx.doi.org/10.1016/j.mayocp.2012.03.011
dc.sourceEmery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatol (United Kingdom). 2012;51(SUPPL.5):22–30.
dc.sourceReggia R, Franceschini F, Tincani a., Cavazzana I. Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety. J Rheumatol [Internet]. 2014;42(2):193–5. Available from: http://www.jrheum.org/cgi/doi/10.3899/jrheum.141042
dc.sourceKissin EY. The “dirty little secret” exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy. Clin Ther [Internet]. Elsevier; 2014;36(7):1114–6. Available from: http://dx.doi.org/10.1016/j.clinthera.2014.06.012
dc.sourcePope JE, Rampakakis E, Sampalis J. The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study. Semin Arthritis Rheum [Internet]. Elsevier; 2015;44(5):499–505. Available from: http://linkinghub.elsevier.com/retrieve/pii/S004901721400225X
dc.sourceKokuina E, Chico A, Estevez M, Argüelles A, Casas N, Pérez D et al. Autoanticuerpos diagnósticos en enfermedades autoinmunes sistémicas y específicas de órgano. Rev Cubana Med. 2006;45 (2)
dc.sourceVan den Broek M, Visser K, Allaart CF, Huizinga TWJ. Personalized medicine: predicting responses to therapy in patients with RA. Curr Opin Pharmacol. 2013.13(3):463–9.
dc.sourceArnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315---24.
dc.sourceIsaacs JD, Harari O, Kobold U, Lee JS, Bernasconi C. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther [Internet]. 2013 Jan;15(6):R204.
dc.sourceKaufmann J, Feist E, Roske AE, Schmidt W a. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: Efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol. 2013;32(9):1347–55.
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectTerapia biológica
dc.subjectactividad de la enfermedad
dc.subjectmedicina personalizada
dc.titleFactores asociados a respuesta de abatacept subcutaneo en artritis reumatoide
dc.typebachelorThesis


Este ítem pertenece a la siguiente institución